07:00 , May 23, 2016 |  BC Week In Review  |  Company News

Alexza, Ferrer deal

Grupo Ferrer’s Ferrer Pharma subsidiary will acquire Alexza for $0.90 per share in cash. The deal values Alexza at $19.6 million based on 21.7 million shares outstanding on May 11. Alexza shareholders will also receive...
08:00 , Nov 23, 2015 |  BC Week In Review  |  Company News

Alexza, Teva deal

Alexza will regain U.S. rights to Adasuve loxapine from Teva, effective Jan. 1, 2016. Alexza, which granted Teva U.S rights in 2013, said it plans to identify a new U.S. commercial partner for the product....
07:00 , Oct 19, 2015 |  BC Week In Review  |  Company News

Alexza drug delivery, neurology news

Alexza retained Guggenheim Securities to explore strategic options, including the sale or disposition of one or more corporate assets, a strategic business combination, partnership or other transactions. Alexza’s Adasuve loxapine -- loxapine delivered by the...
07:00 , Jul 20, 2015 |  BC Week In Review  |  Company News

Alexza, Ferrer deal

The companies added the Middle East and North Africa region, Korea, the Philippines and Thailand to a 2011 deal granting Grupo Ferrer exclusive rights to commercialize Adasuve loxapine. Grupo Ferrer now has rights in the...
08:00 , Nov 17, 2014 |  BC Week In Review  |  Company News

Alexza, Ferrer deal

The companies eliminated undisclosed milestone payments under a 2011 deal granting Grupo Ferrer exclusive rights to commercialize bipolar disorder and schizophrenia product Adasuve loxapine in Europe, Latin America and the Commonwealth of Independent States. In...
07:00 , Aug 11, 2014 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes...
07:00 , May 19, 2014 |  BC Week In Review  |  Company News

Ferrer, Medivir sales and marketing update

Medivir launched Adasuve loxapine in Sweden, Norway, Finland and Denmark to treat mild to moderate agitation in adults with schizophrenia or bipolar disorder. Medivir has exclusive, Nordic commercialization rights to Adasuve from Ferrer under a...
07:00 , Mar 24, 2014 |  BC Week In Review  |  Financial News

Alexza completes private placement of senior notes

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA), Mountain View, Calif.   Business: Drug delivery, Neurology   Date completed: 3/19/14   Type: Private placement of senior notes   Raised: $45 million   Placement agent: Morgan Stanley   Investors: Institutional...
07:00 , Mar 24, 2014 |  BioCentury  |  Finance

Highlights of weekly biotech stock moves

Regulatory milestones AB Science S.A. (Euronext:AB) fell €1.61 (11%) to €12.67 on Friday after EMA's CHMP again recommended against conditional approval of masitinib for second-line treatment of gastrointestinal stromal tumors. AB Science was appealing a...
07:00 , Mar 24, 2014 |  BioCentury  |  Strategy

A Remembrance: The quintessential serial entrepreneur

Very few of us will live as long, invent as much, or improve as many lives as Alejandro Zaffaroni. Alex, who was 91 when he passed away this month, already was an eminence grise in...